Taiwan Bio-Pharma Association Leads Cross-Border Medical Investment, Expanding Overseas Industry Opportunities

The Chinese Biotechnology and Pharmaceutical Industry Association (CBIA) held its "Second First Member Meeting and International Overseas Capital Development Strategic Agreement" on May 22 at the National Taiwan University Alumni Association. Vice President Yang Danjie of the Taipei Association in India, President Liu Yichuan of the Legislative Yuan's Association of Taiwan and ASEAN Legislators, President Huang Zhenggang of the CBIA Vietnam Branch, CEO Chen Xiangyu of Chuangyi Group, and representatives from various pharmaceutical associations attended the event. Special guest Zhang Zhonglin, director of the Ho Chi Minh City Medical Clinic, also joined to witness new opportunities for Taiwan's biotechnology and pharmaceutical overseas trade.

Taiwan Brand, Taiwan Technology, ASEAN Manufacturing, Global Marketing.

During the member meeting, the "Legislative Yuan's Sub-group Strategy for Expanding into the ASEAN Market" was also held. This exchange activity aimed to integrate resources from industry, government, academia, and research and development units, grasp the secondary industry demands of key sectors, assist industries in cultivating technological capabilities, promote cross-industry alliances and exchanges, strengthen industrial capacity, create cooperation opportunities, and enhance industry competitiveness. Chairman Chen Jianzhou stated that Taiwan has an excellent healthcare system and a complete information and communication technology supply chain, along with a strong pool of biomedical and technology talent. The Executive Yuan is coordinating cross-ministry resources to jointly promote Taiwan's precision health industry and encourages the ICT industry to invest in this sector. He believes that there will be more cooperation opportunities in the international economic and trade exchanges of the overseas biomedical industry in the future.

Signing of MOU Strategic Agreement and Establishment of Office in Malaysia.

Chen Jianzhou, Chairman of the Chinese Biotechnology and Pharmaceutical Industry Association, Lin Fenglan, Secretary-General of the Taiwan Global Trade and Logistics Development Association, and Zhou Xunyu, CEO of Haomaji Co., Ltd., jointly signed the MOU strategic agreement for the establishment of an office in Malaysia. Haomaji is willing to provide support for both associations to set up an office in Malaysia. Secretary-General Lin Fenglan stated that the three parties will join forces, share resources, and combine advantages to create a new business model for all-channel commerce, assisting companies in expanding overseas opportunities. CEO Zhou Xunyu mentioned that Haomaji's mission is to establish a safe and convenient cross-border platform that provides solutions for business flow, logistics, and information flow, making cross-border business simpler. From June 4 to 8, a Malaysian pharmaceutical delegation will visit Kuala Lumpur to sign a cooperation agreement with Ivan Chen, President of Malaysia, to assist with pharmaceutical certification matters.

Five Safe Medicine Alliances Recognized for Their Commitment to Public Health.

"Safe Food, Safe Medicine" is the mission of the Food and Drug Administration. Both food and pharmaceuticals are subject to legal regulations, as laws represent the minimum standards of ethics. The Safe Medicine Alliance is a certification initiative launched by the industry, applicable to distribution channels (hospitals, clinics, pharmacies, and long-term care institutions) and biotechnology pharmaceutical manufacturers on the supply side. The three main objectives of the Safe Medicine Alliance are "Product Safety, Service Safety, and Location Safety." Certified entities must not provide counterfeit or inferior products, should offer correct pharmaceutical services and professional consultations, and their retail locations (distribution channels) and manufacturing sites (supply side) must comply with legal regulations. Under the witness of our public interest lawyer Zhang Genghao, 22 well-known companies have joined the Safe Medicine Alliance. During this member meeting, five biotechnology pharmaceutical companies were recognized: Zhu San Industrial Co., Ltd., Yueshi Health Co., Ltd., Fecula Biotechnology Co., Ltd., Internet Intelligence Co., Ltd., and Pharmaceutical Talent Management Consulting Co., Ltd., promoting quality upgrades in the pharmaceutical industry and jointly safeguarding public health.